V

Valley Research | Fresno, CA

Research site
(Unclaimed)
Location
550 E. Herndon Avenue, Suite 101, Fresno, California, United States of America
Site insights

Top conditions

Diabetes Mellitus (43 trials)

Type 2 Diabetes Mellitus (35 trials)

Type 1 Diabetes Mellitus (11 trials)

Obesity (7 trials)

Overweight (6 trials)

Top treatments

Tirzepatide
LY3298176
Dapagliflozin
BMS-512148
Glucose
AC2993
Tanezumab
LY900014
Semaglutide
LY3437943

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

14 of 68
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The st...

Enrolling
Diabetes Mellitus, Type 2
Drug: NNC0519-0130
Drug: Placebo

This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 dia...

Enrolling
Obesity
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Insuline glargine U100 (reduced)

The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 dia...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)

This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesit...

Enrolling
Chronic Kidney Disease
Obesity
Drug: Semaglutide
Drug: Placebo

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The purpose of this study is to determine the effect and safety of insulin efsitora alfa (LY3209590) compared to degludec in adult participants with...

Active, not recruiting
Diabetes
Type 2 Diabetes
Drug: Insulin Degludec
Drug: Insulin Efsitora Alfa

The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participa...

Active, not recruiting
Diabetes
Type 1 Diabetes
Drug: Insulin Degludec
Drug: Insulin Efsitora Alfa

The reason for this study is to see if the study drug insulin efsitora alfa (LY3209590) is safe and effective in participants with Type 2 diabetes th...

Active, not recruiting
Type 2 Diabetes
Drug: Insulin Efsitora Alfa
Drug: Insulin Degludec

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master pr...

Enrolling
Overweight
Knee Pain Chronic
Drug: Retatrutide
Drug: Placebo

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiov...

Enrolling
Obesity
Cardiovascular Diseases
Drug: Placebo
Drug: Retatrutide

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weig...

Active, not recruiting
Overweight
Obesity
Drug: Tirzepatide
Drug: Placebo
Locations recently updated

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

This global study (US, Canada, and Australia) will evaluate the safety and effectiveness of the MiniMed 780G system in type 1 adult and pediatric sub...

Active, not recruiting
Type 1 Diabetes
Device: MiniMed 780G System

Trial sponsors

Lilly logo

Lilly (19 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems